New Gene Editing Trial Results Bump the ARKG ETF
June 29, 2021 at 11:10 AM EDT
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged Monday after the firm and another company known as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) over the weekend announced positive results from an ongoing Phase I clinical trial for an in vivo genome editing therapy known as NTLA-2001....
